Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XLO
- Price
- 0.68
- Stock movement up
- +0.03 (5.33%)
- Company name
- Xilio Development Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 29.89M
- Ent value
- 22.32M
- Price/Sales
- 3.97
- Price/Book
- 1.43
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -53.74%
- 3 year return
- -54.31%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-10
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
XLO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.97 |
| Price to Book | 1.43 |
| EV to Sales | 2.97 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 43.96M |
| EPS (TTM) | -0.71 |
| FCF per share (TTM) | -0.11 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 7.52M |
| Gross profit (TTM) | 3.73M |
| Operating income (TTM) | -45.98M |
| Net income (TTM) | -45.15M |
| EPS (TTM) | -0.71 |
| EPS (1y forward) | -0.67 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 49.61% |
| Operating margin (TTM) | -611.21% |
| Profit margin (TTM) | -600.21% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 61.26M |
| Net receivables | 0.00 |
| Total current assets | 63.31M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 74.66M |
| Accounts payable | 972.00K |
| Short/Current long term debt | 8.41M |
| Total current liabilities | 38.02M |
| Total liabilities | 53.68M |
| Shareholder's equity | 20.97M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -4.22M |
| Capital expenditures (TTM) | 30.00K |
| Free cash flow (TTM) | -7.18M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -215.26% |
| Return on Assets | -60.47% |
| Return on Invested Capital | -204.05% |
| Cash Return on Invested Capital | -32.43% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.64 |
| Daily high | 0.70 |
| Daily low | 0.63 |
| Daily Volume | 296K |
| All-time high | 25.11 |
| 1y analyst estimate | 4.50 |
| Beta | -0.20 |
| EPS (TTM) | -0.71 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 Jun 2025 |
Downside potential
Loading...
Downside potential data
| XLO | S&P500 | |
| Current price drop from All-time high | -97.29% | -10.49% |
| Highest price drop | -98.01% | -56.47% |
| Date of highest drop | 20 Dec 2023 | 9 Mar 2009 |
| Avg drop from high | -85.79% | -11.07% |
| Avg time to new high | 97 days | 12 days |
| Max time to new high | 852 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
29.89M
Marketcap category
Small-cap
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Employees
73
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page